StockNews.AI
ADTX
StockNews.AI
11 days

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

1. Aditxt's subsidiary, Pearsanta, received IRB approval for endometriosis test study. 2. The Mitomic® Endometriosis Test aims to improve early detection of endometriosis.

2 mins saved
Full Article

FAQ

Why Bullish?

IRB approval can lead to potential market success, similar to other health diagnostics that gained popularity post-approval.

How important is it?

The approval marks significant progress for ADTX's pipeline, which can attract investors and increase stock value.

Why Short Term?

Initial study outcomes will quickly influence stock performance as early detection is crucial in the healthcare market.

Related Companies

WCGHIMSDQMS
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has received Institutional Review Board (IRB) approval from WCG Clinical to initiate a prospective clinical study evaluating the Mitomic® Endometriosis Test (MET), a novel blood-based diagnostic designed to aid in the early detection of endometriosis. The study,.

Related News